Marco Ruella, MD

faculty photo
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations

Contact information
South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004
Office: 215-746-4880
Fax: 215-573-3638
Lab: 215-573-8538
Education:
MD (Medical Degree)
University of Torino, Italy , 2007.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Dr. Ruella treat patients affected by hematological cancers and specializes in immunotherapy approaches.

Description of Research Expertise

Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.

Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. He was attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was an Instructor at the Biotechnology School at the University of Torino. From late 2012, he was a Post-doctoral Fellow, and then an Instructor at the University of Pennsylvania in the Center for Cellular immunotherapies (Drs. June and Gill). From 2017 to 2018 he served as Associate Director of Dr. June’s laboratory. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Dr. Ruella was awarded many awards and honors, including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), the 2018 ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, the Gilead Sciences Research Scholar in Hematology/Oncology and the Gabrielle’s Angel Foundation Award (2020), and the Leukemia and Lymphoma Society, Translational Research Program (2021). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CART therapy and the Scientific Founder of viTToria biotherapeutics.

Selected Publications

Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M.: Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer. Cancer Discov Jul 2022.

Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M.: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med April 2022.

Ki-Hyun Kim, Soohwan Kim, Ji-Hyeon Choi, Sung-Min Kim, Gae-Baik Kim, Jong-Ho Lee, Hyun-Jong Lee, Sang-Ho Ahn, Guewha Lee, LeiGuang Cui, Seong Yeol Kim, Min Yoon, Ki Hyun Kim, Soohyun Kim, Juwon Lee, Youngjin Han, Youngha Lee, In-Sik Hwang, Bong-Kook Ko, Jong-Seo Lee, Yong Sang Song, Ruella M, Junho Chung. : A novel cotinine-based system for switchable chimeric antigen receptor T cell immunotherapy. American Assoication of Cancer Research Annual Meeting, Miami Beach,FL Apr-May 2021 Notes: "Poster Presentation" LB149.

Charly R. Good, Shunichiro Kuramitsu, Parisa Samareh, Greg Donahue, Kenichi Ishiyama, Yujie Ma, Nils Wellhausen, Lifeng Tian, Sangya Agarwal, Sonia Guedan, M. Angela Aznar, Katherine A. Alexander, Zhen Zhang, Nathan Singh, Max W. Richardson, Keisuke Watanabe, Janos L. Tanyi, Mark H. O’Hara, Marco Ruella, Simon F. Lacey, Edmund K. Moon, Stephen J. Schuster, Steven M. Albelda, Lewis L. Lanier, Regina M. Young, Shelley L. Berger, Carl H. June. : Induction of T cell dysfunction and NK-like T cell differentiation in vitro and in patients after CAR T cell treatment American Association of Cancer Research Annual Meeting, Miami Beach, FL Apr-May 2021 Notes: "Poster Presentation" #60.

Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH.: An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184: 6081-6100, Dec 2021.

Ghilardi G, Chong E.A., Svoboda J, Wohlfarth P, Nasta S.D., Williamson S, Landsburg D.J., Gerson J.N., Barta S.K., Pajarillo R, Myers J, Yelton R, Ballard H.J., Gier S.H., Victoriano D, Weber E, Napier E, Lacey S.F., Garfall1 A.L., Porter D.L., Jaeger U, Maziarz R.T., Ruella M, and Schuster S.J.: Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas American Society of Hematology Annual Meeting, Atlanta, GA. Dec 2021 Notes: "Poster Presentation" #1438.

Smith M, Dai A, Ghilardi G, Amelsberg K, Devlin S.M., Pajarillo R, Slingerland J.B., Beghi S, Herrera P.S., Giardina P.A., Clurman A, Dwomoh E.A., Armijo G.K., Antonio L.C. Gomes A.L.C., Littmann E.R., Schluter J, Fontana E, Taur Y, Park J.H., Palomba M.L., Halton E, Ruiz J.D., Jain T, Pennisi M, Afuye A.O., Perales MA, Freyer C.W., Garfall A.L., Gier S.H., Nasta S, Landsburg D.J., Gerson J.N., Svoboda J, Cross J, Chong E.A., Giralt S.A., Gill S, Rivière I, Porter D.L., Schuster S.J., Sadelain M, Frey N.V., Brentjens R.J., June C.H., Pamer E.G., Peled J.U., Ruella M, van den Brink M, and Facciabene A: The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies ASH American Society of Hematology Annual Meeting, Atlanta, GA Dec 2021 Notes: "Poster Presentation" abstract #253.

Patel R, Kim KH, Lee YG, Guruprasad P, Kim S, Choi JH, Kim SM, Kim GB, Lee JH, Lee HJ, Park JH, Lee G, Cui LG, Yoon M, Kim KH, Kim S, Hwang IS, Lee Y, Lee J.S., Chung J, and Ruella M: A Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19. American Society of Hematology Annual Meeting, Atlanta, GA Dec 2021 Notes: "Poster Presentation" #2798.

Ruff A, Ballard HJ, Pantel AR, Namoglu EC, Hughes ME, Nasta SD, Chong EA, Bagg A, Ruella M, Farwell MD, Svoboda J, Sellmyer MA.: (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Mol Imaging Biol 23(6): 818-826, Dec 2021.

Lemoine J, Ruella M, Houot R.: Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing. Clin Cancer Res 27(23): 6298-6306, Dec 2021.

back to top
Last updated: 08/25/2022
The Trustees of the University of Pennsylvania